{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:35:01Z","timestamp":1740123301767,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"crossref","award":["H2020206003","H2020206003"],"award-info":[{"award-number":["H2020206003","H2020206003"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFE0203000"],"award-info":[{"award-number":["2020YFE0203000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970120, 81770128, 81900249"],"award-info":[{"award-number":["81970120, 81770128, 81900249"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Project of Science and Technology Research Project of Hebei Universities","award":["ZD2021069"],"award-info":[{"award-number":["ZD2021069"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10637-022-01297-5","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T08:04:03Z","timestamp":1661933043000},"page":"1194-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations"],"prefix":"10.1007","volume":"40","author":[{"given":"Jiajia","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzhe","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"1297_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"1297_CR2","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet 365:1054\u20131061. https:\/\/doi.org\/10.1016\/s0140-6736(05)71142-9","journal-title":"The Lancet"},{"key":"1297_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/gcc.21960","volume":"51","author":"M Brecqueville","year":"2012","unstructured":"Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A (2012) Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 51:743\u2013755. https:\/\/doi.org\/10.1002\/gcc.21960","journal-title":"Genes Chromosomes Cancer"},{"key":"1297_CR4","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NCP, Tefferi A (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27:1861\u20131869. https:\/\/doi.org\/10.1038\/leu.2013.119","journal-title":"Leukemia"},{"key":"1297_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41408-020-00364-5","volume":"10","author":"Y-H Wang","year":"2020","unstructured":"Wang Y-H, Lin C-C, Lee S-H, Tsai C-H, Wu S-J, Hou H-A, Huang T-C, Kuo Y-Y, Yao M, Chang K, Lin C-W, Lin Y-C, Tien F-M, Chou W-C, Tang J-L, Tien H-F (2020) ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden. Blood Cancer J 10:99. https:\/\/doi.org\/10.1038\/s41408-020-00364-5","journal-title":"Blood Cancer J"},{"key":"1297_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41375-018-0347-y","volume":"33","author":"Y Guo","year":"2019","unstructured":"Guo Y, Zhou Y, Yamatomo S, Yang H, Zhang P, Chen S, Nimer SD, Zhao ZJ, Xu M, Bai J, Yang FC (2019) ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Leukemia 33:1287\u20131291. https:\/\/doi.org\/10.1038\/s41375-018-0347-y","journal-title":"Leukemia"},{"key":"1297_CR7","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","volume":"119","author":"A Tefferi","year":"2012","unstructured":"Tefferi A (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119:2721\u20132730. https:\/\/doi.org\/10.1182\/blood-2011-11-395228","journal-title":"Blood"},{"key":"1297_CR8","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/cncr.34216","volume":"128","author":"F Palandri","year":"2022","unstructured":"Palandri F, Bartoletti D, Iurlo A, Bonifacio M, Abruzzese E, Caocci G, Elli EM, Auteri G, Tiribelli M, Polverelli N, Miglino M, Heidel FH, Tieghi A, Benevolo G, Beggiato E, Fava C, Cavazzini F, Pugliese N, Binotto G, Bosi C, Martino B, Crugnola M, Ottaviani E, Micucci G, Trawinska MM, Cuneo A, Bocchia M, Krampera M, Pane F, Lemoli RM, Cilloni D, Vianelli N, Cavo M, Palumbo GA, Breccia M (2022) Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. Cancer 128:2449\u20132454. https:\/\/doi.org\/10.1002\/cncr.34216","journal-title":"Cancer"},{"key":"1297_CR9","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1002\/cncr.33094","volume":"126","author":"L Masarova","year":"2020","unstructured":"Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S (2020) Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer 126:4322\u20134331. https:\/\/doi.org\/10.1002\/cncr.33094","journal-title":"Cancer"},{"key":"1297_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cncr.32664","volume":"126","author":"F Palandri","year":"2020","unstructured":"Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Fo\u00e0 R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N (2020) Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 126:1243\u20131252. https:\/\/doi.org\/10.1002\/cncr.32664","journal-title":"Cancer"},{"key":"1297_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","volume":"97","author":"AT Kuykendall","year":"2018","unstructured":"Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS (2018) Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol 97:435\u2013441. https:\/\/doi.org\/10.1007\/s00277-017-3194-4","journal-title":"Ann Hematol"},{"key":"1297_CR12","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.3324\/haematol.2018.209965","volume":"104","author":"ST Durrant","year":"2019","unstructured":"Durrant ST, Nagler A, Guglielmelli P, Lavie D, le Coutre P, Gisslinger H, Chuah C, Maffioli M, Bharathy S, Dong T, Wroclawska M, Lopez JM (2019) Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica 104:e551\u2013e554. https:\/\/doi.org\/10.3324\/haematol.2018.209965","journal-title":"Haematologica"},{"key":"1297_CR13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa1310523","volume":"373","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, Laborde RR, Wassie E, Schimek L, Hanson CA, Gangat N, Wang X, Pardanani A (2015) A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med 373:908\u2013919. https:\/\/doi.org\/10.1056\/NEJMoa1310523","journal-title":"N Engl J Med"},{"key":"1297_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.yexcr.2015.04.016","volume":"335","author":"Z Fan","year":"2015","unstructured":"Fan Z, Yu H, Cui N, Kong X, Liu X, Chang Y, Wu Y, Sun L, Wang G (2015) ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics. Exp Cell Res 335:68\u201381. https:\/\/doi.org\/10.1016\/j.yexcr.2015.04.016","journal-title":"Exp Cell Res"},{"key":"1297_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1124\/mol.109.060780","volume":"77","author":"LM High","year":"2010","unstructured":"High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O\u2019Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB (2010) The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 77:483\u2013494. https:\/\/doi.org\/10.1124\/mol.109.060780","journal-title":"Mol Pharmacol"},{"key":"1297_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","volume":"140","author":"J Kuroda","year":"2008","unstructured":"Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T (2008) ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 140:181\u2013190. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06899.x","journal-title":"Br J Haematol"},{"key":"1297_CR17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2005.05.026","volume":"121","author":"MJ Kiel","year":"2005","unstructured":"Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ (2005) SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121:1109\u20131121. https:\/\/doi.org\/10.1016\/j.cell.2005.05.026","journal-title":"Cell"},{"key":"1297_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/gt.2009.138","volume":"17","author":"P Laje","year":"2010","unstructured":"Laje P, Zoltick PW, Flake AW (2010) SLAM-enriched hematopoietic stem cells maintain long-term repopulating capacity after lentiviral transduction using an abbreviated protocol. Gene Ther 17:412\u2013418. https:\/\/doi.org\/10.1038\/gt.2009.138","journal-title":"Gene Ther"},{"key":"1297_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375\u2013388. https:\/\/doi.org\/10.1016\/j.ccr.2006.10.006","journal-title":"Cancer Cell"},{"key":"1297_CR20","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1172\/jci98785","volume":"129","author":"S Stivala","year":"2019","unstructured":"Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC (2019) Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest 129:1596\u20131611. https:\/\/doi.org\/10.1172\/jci98785","journal-title":"J Clin Invest"},{"key":"1297_CR21","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP, Staerk J, Delhommeau F, Lacout C, Gar\u00e7on L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144\u20131148. https:\/\/doi.org\/10.1038\/nature03546","journal-title":"Nature"},{"key":"1297_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.phrs.2015.09.022","volume":"102","author":"O Tetsu","year":"2015","unstructured":"Tetsu O, Phuchareon J, Eisele DW, Hangauer MJ, McCormick F (2015) AKT inactivation causes persistent drug tolerance to EGFR inhibitors. Pharmacol Res 102:132\u2013137. https:\/\/doi.org\/10.1016\/j.phrs.2015.09.022","journal-title":"Pharmacol Res"},{"key":"1297_CR23","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker W, Constantinescu SN (2013) JAK\/STAT signaling in hematological malignancies. Oncogene 32:2601\u20132613. https:\/\/doi.org\/10.1038\/onc.2012.347","journal-title":"Oncogene"},{"key":"1297_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D\u2019Andrea A, Fr\u00f6hling S, D\u00f6hner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397. https:\/\/doi.org\/10.1016\/j.ccr.2005.03.023","journal-title":"Cancer Cell"},{"key":"1297_CR25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S (2008) The natural history and treatment outcome of blast phase BCR-ABL\u2212 myeloproliferative neoplasms. Blood 112:1628\u20131637. https:\/\/doi.org\/10.1182\/blood-2008-02-138230","journal-title":"Blood"},{"key":"1297_CR26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/jco.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392\u2013397. https:\/\/doi.org\/10.1200\/jco.2010.32.2446","journal-title":"J Clin Oncol"},{"key":"1297_CR27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","volume":"92","author":"M Yogarajah","year":"2017","unstructured":"Yogarajah M, Tefferi A (2017) Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. Mayo Clin Proc 92:1118\u20131128. https:\/\/doi.org\/10.1016\/j.mayocp.2017.05.010","journal-title":"Mayo Clin Proc"},{"key":"1297_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","volume":"22","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22:180\u2013193. https:\/\/doi.org\/10.1016\/j.ccr.2012.06.032","journal-title":"Cancer Cell"},{"key":"1297_CR29","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/leu.2009.141","volume":"23","author":"N Carbuccia","year":"2009","unstructured":"Carbuccia N, Murati A, Trouplin V, Brecqueville M, Ad\u00e9la\u00efde J, Rey J, Vainchenker W, Bernard OA, Chaffanet M, Vey N, Birnbaum D, Mozziconacci MJ (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23:2183\u20132186. https:\/\/doi.org\/10.1038\/leu.2009.141","journal-title":"Leukemia"},{"key":"1297_CR30","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1200\/jco.2010.33.4938","volume":"29","author":"F Thol","year":"2011","unstructured":"Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, G\u00f6hring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A (2011) Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 29:2499\u20132506. https:\/\/doi.org\/10.1200\/jco.2010.33.4938","journal-title":"J Clin Oncol"},{"key":"1297_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/0008-5472.Can-09-3783","volume":"70","author":"O Abdel-Wahab","year":"2010","unstructured":"Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S (2010) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70:447\u2013452. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-3783","journal-title":"Cancer Res"},{"key":"1297_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature11303","volume":"489","author":"P Koppikar","year":"2012","unstructured":"Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, G\u00f6nen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489:155\u2013159. https:\/\/doi.org\/10.1038\/nature11303","journal-title":"Nature"},{"key":"1297_CR33","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","volume":"123","author":"N Bhagwat","year":"2014","unstructured":"Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, Qi J, Kleppe M, Patel HJ, Shah SK, Taldone T, Bradner JE, Chiosis G, Levine RL (2014) Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood 123:2075\u20132083. https:\/\/doi.org\/10.1182\/blood-2014-01-547760","journal-title":"Blood"},{"key":"1297_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/17474086.2018.1453802","volume":"11","author":"SR Bohl","year":"2018","unstructured":"Bohl SR, Bullinger L, R\u00fccker FG (2018) Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol 11:361\u2013371. https:\/\/doi.org\/10.1080\/17474086.2018.1453802","journal-title":"Expert Rev Hematol"},{"key":"1297_CR35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2217\/fon-2017-0523","volume":"14","author":"G Montalban-Bravo","year":"2018","unstructured":"Montalban-Bravo G, DiNardo CD (2018) The role of IDH mutations in acute myeloid leukemia. Future Oncol 14:979\u2013993. https:\/\/doi.org\/10.2217\/fon-2017-0523","journal-title":"Future Oncol"},{"key":"1297_CR36","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1111\/bjh.16709","volume":"190","author":"AA Patel","year":"2020","unstructured":"Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, Kosuri S, Artz AS, Larson RA, Stock W, Segal J, Odenike O (2020) Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol 190:e48\u2013e51. https:\/\/doi.org\/10.1111\/bjh.16709","journal-title":"Br J Haematol"},{"key":"1297_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/nejm199802263380902","volume":"338","author":"M Silva","year":"1998","unstructured":"Silva M, Richard C, Benito A, Sanz C, Olalla I, Fern\u00e1ndez-Luna JL (1998) Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 338:564\u2013571. https:\/\/doi.org\/10.1056\/nejm199802263380902","journal-title":"N Engl J Med"},{"key":"1297_CR38","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","volume":"108","author":"L Gar\u00e7on","year":"2006","unstructured":"Gar\u00e7on L, Rivat C, James C, Lacout C, Camara-Clayette V, Ugo V, Lecluse Y, Bennaceur-Griscelli A, Vainchenker W (2006) Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 108:1551\u20131554. https:\/\/doi.org\/10.1182\/blood-2005-10-009514","journal-title":"Blood"},{"key":"1297_CR39","doi-asserted-by":"publisher","unstructured":"Coultas L, Strasser A (2003) The role of the Bcl-2 protein family in cancer. Seminars in Cancer Biol 13:115\u2013123. https:\/\/doi.org\/10.1016\/S1044-579X(02)00129-3","DOI":"10.1016\/S1044-579X(02)00129-3"},{"key":"1297_CR40","doi-asserted-by":"crossref","unstructured":"Chauncey TR (2001) Drug resistance mechanisms in acute leukemia. Curr Op Oncol 13","DOI":"10.1097\/00001622-200101000-00005"},{"key":"1297_CR41","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/sj.leu.2401571","volume":"13","author":"V Nuessler","year":"1999","unstructured":"Nuessler V, St\u00f6tzer O, Gullis E, Pelka-Fleischer R, Pogrebniak A, Gieseler F, Wilmanns W (1999) Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia 13:1864\u20131872. https:\/\/doi.org\/10.1038\/sj.leu.2401571","journal-title":"Leukemia"},{"key":"1297_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1756-8722-5-2","volume":"5","author":"R Tognon","year":"2012","unstructured":"Tognon R, Gasparotto EP, Neves RP, Nunes NS, Ferreira AF, Palma PV, Kashima S, Covas DT, Santana M, Souto EX, Zanichelli MA, Sim\u00f5es BP, de Souza AM, Castro FA (2012) Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis. J Hematol Oncol 5:2. https:\/\/doi.org\/10.1186\/1756-8722-5-2","journal-title":"J Hematol Oncol"},{"key":"1297_CR43","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2008-03-143321","volume":"113","author":"A Zeuner","year":"2009","unstructured":"Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A, De Maria R (2009) Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood 113:1522\u20131525. https:\/\/doi.org\/10.1182\/blood-2008-03-143321","journal-title":"Blood"},{"issue":"748\u2013764","key":"1297_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.07.021","volume":"27","author":"CL Jones","year":"2020","unstructured":"Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajuddin M, Abbott D, Becker MW, DeGregori J, Smith CA, D\u2019Alessandro A, Jordan CT (2020) Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell 27(748\u2013764):e4. https:\/\/doi.org\/10.1016\/j.stem.2020.07.021","journal-title":"Cell Stem Cell"},{"key":"1297_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.Cd-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, D\u00f6hner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, M\u00fcschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG (2014) Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. Cancer Discov 4:362\u2013375. https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-0609","journal-title":"Cancer Discov"},{"key":"1297_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","volume":"11","author":"NE Rahmani","year":"2021","unstructured":"Rahmani NE, Ramachandra N, Sahu S, Gitego N, Lopez A, Pradhan K, Bhagat TD, Gordon-Mitchell S, Pena BR, Kazemi M, Rao K, Giricz O, Maqbool SB, Olea R, Zhao Y, Zhang J, Dolatshad H, Tittrea V, Tatwavedi D, Singh S, Lee J, Sun T, Steidl U, Shastri A, Inoue D, Abdel-Wahab O, Pellagatti A, Gavathiotis E, Boultwood J, Verma A (2021) ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer J 11:157. https:\/\/doi.org\/10.1038\/s41408-021-00541-0","journal-title":"Blood Cancer J"},{"key":"1297_CR47","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/s41467-021-22053-y","volume":"12","author":"T Fujino","year":"2021","unstructured":"Fujino T, Goyama S, Sugiura Y, Inoue D, Asada S, Yamasaki S, Matsumoto A, Yamaguchi K, Isobe Y, Tsuchiya A, Shikata S, Sato N, Morinaga H, Fukuyama T, Tanaka Y, Fukushima T, Takeda R, Yamamoto K, Honda H, Nishimura EK, Furukawa Y, Shibata T, Abdel-Wahab O, Suematsu M, Kitamura T (2021) Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt\/mTOR pathway. Nat Commun 12:1826. https:\/\/doi.org\/10.1038\/s41467-021-22053-y","journal-title":"Nat Commun"},{"issue":"7","key":"1297_CR48","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s13238-020-00754-2","volume":"12","author":"YK Xia","year":"2021","unstructured":"Xia YK, Zeng YR, Zhang ML, Liu P, Liu F, Zhang H, He CX, Sun YP, Zhang JY, Zhang C, Song L, Ding C, Tang YJ, Yang Z, Yang C, Wang P, Guan KL, Xiong Y, Ye DA-O (2021) Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1\/K2 transcription network. Protein Cell 12(7):557\u2013577. https:\/\/doi.org\/10.1007\/s13238-020-00754-2","journal-title":"Protein Cell"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01297-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:52:43Z","timestamp":1678510363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01297-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01297-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this project was obtained from the Ethics Committee of Blood Diseases Hospital, Chinese Academy of Medical Sciences. Four patient samples were collected and processed immediately after bone marrow puncture. Written informed consent was obtained according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.\u00a0The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}